OLMAOlema Pharmaceuticals, Inc.
$7.81-25% 1Y
$7.81
$7.7752 weeks$35.83
OLMA as reported
- Net income
- −$205M
Net income · +44% year on year · trailing twelve months to Q2 2026
- EPS
- −$2.13
EPS · +14% year on year · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net income | −$205M | +44% | Q2 2026 |
| EPS | −$2.13 | +14% | Q2 2026 |
| ROE | −42% | n/a | Q2 2026 |
| ROA | −37% | n/a | Q2 2026 |
| Free cash flow | −$105M | n/a | Q4 2024 · 6 quarters behind |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
Olema Pharmaceuticals, Inc. (OLMA) · Net incomeNet incomeOlema Pharmaceuticals, Inc. (OLMA)